Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,701–2,800 of 10,906
Vaccination Disparity: Quantifying Racial Inequity in COVID-19 Vaccine Administration in Maryland
Cardona, S., Felipe, N., Fischer, K. R., Sehgal, N. J., & Schwartz, B. E. (2021) · Journal of Urban Health · doi:10.1007/s11524-021-00551-0 · Cited by 28
First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report
Osmanodja, B., Schreiber, A., Schrezenmeier, E. V., & Seelow, E. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02616-3 · Cited by 27
Felten, R., Dubois, M., Ugarte-Gil, M. F., Chaudier, A., Kawka, L., Bergier, H., Costecalde, C., Pijnenburg, L., Fort, J., Chatelus, E., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab432 · Cited by 30
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
Fabris, M., Marchi, G. D., Domenis, R., Caponnetto, F., Guella, S., Secco, C. D., Cabas, N., Vita, S. D., Beltrami, A. P., Curcio, F., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102827 · Cited by 38
Nakahara, T., Iwabuchi, Y., Miyazawa, R., Tonda, K., Shiga, T., Strausś, H. W., Antoniades, C. A., Narula, J., & Jinzaki, M. (2023) · Radiology · doi:10.1148/radiol.230743 · Cited by 31
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
Güven, D. C., Şahin, T. K., Kılıçkap, S., & Uckun, F. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759108 · Cited by 27
Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased
Diebold, M., Locher, E., Boide, P., Enzler-Tschudy, A., Faivre, A., Fischer, I., Helmchen, B., Hopfer, H., Kim, M. J., Moll, S., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.021 · Cited by 30
Witkowski, W., Gerlo, S., Smet, E. D., Wejda, M., Acar, D. D., Callens, S. F. J., Heytens, S., Padalko, E. Y., Vercruysse, H., Cools, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10020260 · Cited by 28
Advances in mRNA-based drug discovery in cancer immunotherapy
Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 29
Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
Robinson, L. B., Landman, A., Shenoy, E. S., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.05.031 · Cited by 28
Seefeld, M. L., Templeton, E. L., Lehtinen, J. M., Sinclair, N., Yadav, D., & Hartwell, B. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419527 · Cited by 35
Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting
Yap, J. J. L., Tham, M. Y., Poh, J. W. W., Toh, D., Chan, C. L., Lim, T. W., Lim, S. L., Chia, Y. W., Lim, Y. T., Choo, J. T. L., et al. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021425 · Cited by 31
Vikström, L., Fjällström, P., Gwon, Y.-D., Sheward, D. J., Byström, J. W., Evander, M., Bladh, O., Widerström, M., Molnár, C., Rasmussen, G., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100646 · Cited by 32
Coulaud, P.-J., Ablona, A., Bolduc, N., Fast, D., Bertrand, K., Ward, J. K., Greyson, D. L., Jauffret‐Roustide, M., & Knight, R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.085 · Cited by 29
Miguel, C. P. V., Dasgupta-Tsinikas, S., Lamb, G. S., Olarte, L., & Santos, R. P. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac099 · Cited by 29
Kavikondala, S., Haeussler, K., Wang, X., Bausch-Jurken, M. T., Nassim, M., Mishra, N. K., Malmenäs, M., Sharma, P., de Velde, N. V., Green, N., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00936-z · Cited by 25
Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
Zhang, H., Jia, Y., Ji, Y., Xu, C., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.816778 · Cited by 29
Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates
Franko, N., Teixeira, A. P., Xue, S., Hamri, G. C., & Fussenegger, M. (2021) · Nature Communications · doi:10.1038/s41467-021-27072-3 · Cited by 27
Determinants of COVID-19 vaccine hesitancy in French hospitals
Navarre, C., Roy, P., Ledochowski, S., Fabre, M., Esparcieux, A., Issartel, B., Dutertre, M., Blanc-Gruyelle, A.-L., Suy, F., Adélaïde, L., et al. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.08.004 · Cited by 27
Yamamoto, K. Z., Yasuo, N., & Sekijima, M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01087 · Cited by 29
Declercq, J., Gerlo, S., Nevel, S. V., Ruyck, N. D., Holtappels, G., Delesie, L. M., Tobback, E., Lammens, I., Gerebtsov, N., Sedeyn, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn2364 · Cited by 31
Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants
Tan, S., Zhao, J., Hu, X., Li, Y., Wu, Z., Lu, G., Yu, Z., Du, B., Liu, Y., Li, L., et al. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.11.024 · Cited by 26
Self-citationMay, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 30
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
(2021) · doi:10.21203/rs.3.rs-156101/v1 · Cited by 728
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 29
Hameed, I., Khan, M. O., Nusrat, K., Mahmood, S., Nashit, M., Malik, S., Siddiqui, O. M., Samad, S. A., Marsia, S., Usman, M., et al. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2022.08.014 · Cited by 33
Busic, N., Lucijanić, T., Baršić, B., Lukšić, I., Bušić, I., Kurdija, G., Barbić, L., Kunštek, S., Jelić, T., & Lucijanić, M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27666 · Cited by 25
MalagodaPathiranage, K., Cavac, E., Chen, T.-H., Roy, B., & Martin, C. T. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad027 · Cited by 34
Modular Integration of Hydrogel Neural Interfaces
Tabet, A., Antonini, M., Sahasrabudhe, A., Park, J., Rosenfeld, D., Koehler, F., Yuk, H., Hanson, S., Stinson, J. A., Stok, M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00592 · Cited by 29
Microneedle‐Mediated Transcutaneous Immunization: Potential in Nucleic Acid Vaccination
Wang, H., Xu, J., & Xiang, L. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300339 · Cited by 33
Lee, S. R., ROH, J., Ryu, J., Shin, H., & Hong, E. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00740-z · Cited by 29
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial
Mostafavi, E., Eybpoosh, S., Karamouzian, M., Khalili, M., Haji‐Maghsoudi, S., Salehi-Vaziri, ., Khamesipour, A., Jalali, T., Nakhaeizadeh, M., Sharifi, H. P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10302 · Cited by 30
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 36
Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination
Krzywicka, K., van de Munckhof, A. A. G. A., van Kammen, M. S., Heldner, M. R., Jood, K., Lindgren, E., Tatlisumak, T., Putaala, J., Hovinga, J. A. K., Middeldorp, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013148 · Cited by 28
Real world effectiveness of covid-19 vaccines
Hungerford, D., & Cunliffe, N. A. (2021) · BMJ · doi:10.1136/bmj.n2034 · Cited by 25
Keppler‐Hafkemeyer, A., Greil, C., Wratil, P. R., Shoumariyeh, K., Stern, M., Hafkemeyer, A., Ashok, D., Hollaus, A., Lupoli, G., Priller, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00502-x · Cited by 33
Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
de Assis, F. L., Hoehn, K. B., Zhang, X., Kardava, L., Smith, C. D., Merhebi, O. E., Buckner, C. M., Trihemasava, K., Wang, W., Seamon, C. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112780 · Cited by 31
Gil-Manso, S., Carbonell, D., López-Fernández, L. A., Miguens, I., Alonso, R., Buño, I., Muñóz, P., Ochando, J., Pion, M., & Correa‐Rocha, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726960 · Cited by 26
Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2
Friedrich, M., Pfeifer, G., Binder, S., Aigner, A. M., Barbosa, P. V., Makert, G. R., Fertey, J., Ulbert, S., Bodem, J., König, E., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.801870 · Cited by 28
COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature
Heldman, M. R., & Kates, O. S. (2021) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-021-00249-6 · Cited by 27
Yanis, A., Haddadin, Z., Spieker, A. J., Waqfi, D., Rankin, D. A., Talj, R., Thomas, L. D., Birdwell, K. A., Ezzell, L. J., Blair, M. A., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13772 · Cited by 33
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 39
Lyu, X., Hu, J., Xu, X., Xianyu, Y., & Dong, W. (2021) · BMC Nursing · doi:10.1186/s12912-021-00591-6 · Cited by 35
Lim, J., Lee, S. A., Khil, E. K., Byeon, S., Kang, H. J., & Choi, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.10.002 · Cited by 28
Modulation of Chitosan-TPP Nanoparticle Properties for Plasmid DNA Vaccines Delivery
Nunes, R. F., Serra, A. S., Simaite, A., et al. (2022) · Polymers · doi:10.3390/polym14071443 · Cited by 27
Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review
He, Y., Ouyang, J., Hu, X.-D., Ni, W., Jiang, Z., Bian, N., & Wang, J. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.892 · Cited by 34
Şendur, S. N., Özmen, F., Oğuz, S. H., İremli, B. G., Malkan, Ü. Y., Gürlek, A., Erbas, T. A., & Ünlütürk, U. (2022) · Thyroid · doi:10.1089/thy.2022.0010 · Cited by 33
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report
Takeyama, R., Fukuda, K., Kouzaki, Y., et al. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-05038-0 · Cited by 27
Left Bell's palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report
Cellina, M. I., D'Arrigo, A. M., Floridi, C., Oliva, G., & Carrafiello, G. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.10.010 · Cited by 27
Bačová, B., Kohutová, Z., Zubata, I. K., Gahérová, Ľ., Kučera, P., Heizer, T., Mikesova, M., Karel, T., & Novák, J. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00809-0 · Cited by 29
Davenport, B., Catala, A., Weston, S. M., Johnson, R. M., Ardanuy, J., Hammond, H., Dillen, C. A., Frieman, M. B., Catalano, C. E., & Morrison, T. E. (2022) · npj Vaccines · doi:10.1038/s41541-022-00481-1 · Cited by 29
CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review
Rinaldi, V., Bellucci, G., Buscarinu, M. C., Reniè, R., Marrone, A., Nasello, M., Zancan, V., Nistri, R., Palumbo, R. A., Salerno, A., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1018785 · Cited by 29
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
Seguí, F. L., Català, M., Prats, C., Estrada, O., Oliva, I., Prat, N., Isnard, M., Vallès, R., Vilar, M., Clotet, B., et al. (2021) · Vaccines · doi:10.3390/vaccines10010059 · Cited by 27
Sharun, K., Singh, R. P., & Dhama, K. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102264 · Cited by 28
COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
Chilimuri, S. S., Mantri, N., Gongati, S., Zahid, M., & Sun, H. (2021) · Vaccines · doi:10.3390/vaccines9030219 · Cited by 28
Nomah, D. K., Reyes‐Urueña, J., Llibre, J. M., Ambrosioni, J., Ganem, F., Miró, J. M., & Casabona, J. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00596-5 · Cited by 32
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 26
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00663 · Cited by 27
Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer
Sanya, D. R. A., Cava, C., & Onésime, D. (2022) · Human Cell · doi:10.1007/s13577-022-00843-w · Cited by 27
Levy, I., Levin, E. G., Olmer, L., Regev‐Yochay, G., Agmon‐Levin, N., Wieder-Finesod, A., Indenbaum, V., Herzog, K. K., Doolman, R., Asraf, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10081220 · Cited by 29
Szebeni, G. J., Gémes, N., Honfi, D., Szabó, E. V., Neuperger, P., Balog, J. Á., Nagy, L. I., Szekanecz, Z., Puskás, L. G., Toldi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846248 · Cited by 36
Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
Barandalla, I., Alvarez-Domínguez, C., Barreiro, P., de Mendoza, C., Crespo, R. A. G., & Soriano, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.022 · Cited by 31
Nature-inspired nanocarriers for improving drug therapy of atherosclerosis
Ji, W., Zhang, Y., Deng, Y., Li, C., Kankala, R. K., & Chen, A. (2023) · Regenerative Biomaterials · doi:10.1093/rb/rbad069 · Cited by 30
Sriwastava, S., Shrestha, A. K., Khalid, S. H., Colantonio, M. A., Nwafor, D. C., & Srivastava, S. (2021) · Neurology International · doi:10.3390/neurolint13040061 · Cited by 27
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
“The robust protection was observed consistently across all assessed age subgroups (18–65 years old) [109].”
BackgroundDutta, T., Baildya, N., Khan, A. A., & Ghosh, N. N. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00309-3 · Cited by 27
Recent advances in versatile inverse lyotropic liquid crystals
Shan, X., Luo, L., Yu, Z., & You, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.036 · Cited by 29
Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Tramontana, F., Battisti, S., Napoli, N., & Strollo, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.726696 · Cited by 30
Shin, H. E., Han, J., Park, J. D., Park, M., Han, J., Kang, M., Lee, J. S., Park, C. G., Park, J., Kim, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202315721 · Cited by 36
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Suzuki, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02566 · Cited by 48
Magicova, M., Zahrádka, I., Fialova, M., Neskudla, T., Gurka, J., Módos, I., Hojny, M., Raška, P., Smejkal, P., Stříž, I., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004044 · Cited by 30
Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies
Orevi, M., Chicheportiche, A., & Ben‐Haim, S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262348 · Cited by 27
Acute pancreatitis soon after COVID-19 vaccination
Ozaka, S., Kodera, T., Ariki, S., et al. (2022) · Medicine · doi:10.1097/md.0000000000028471 · Cited by 27
Sandoval, C., Guerrero, D., Muñoz, J., Godoy, K., Souza‐Mello, V., & Farías, J. G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2156861 · Cited by 31
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 36
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 44
Nanoparticles‐based double‐stranded RNA delivery as an antiviral agent in shrimp aquaculture
Jonjaroen, V., Charoonnart, P., Jitrakorn, S., Payongsri, P., Surarit, R., Saksmerprome, V., & Niamsiri, N. (2024) · Reviews in Aquaculture · doi:10.1111/raq.12916 · Cited by 33
Engineering customized nanovaccines for enhanced cancer immunotherapy
Guo, J., Liu, C., Qi, Z., Qiu, T., Zhang, J. C., & Yang, H. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.02.028 · Cited by 34
Nasir, N. M., Joyosemito, I. S., Boerman, B., & Ismaniah, I. (2021) · Jurnal Pengabdian kepada Masyarakat UBJ · doi:10.31599/jabdimas.v4i2.662 · Cited by 48
Vasculature organotropism in drug delivery
Amruta, A., Iannotta, D., Cheetham, S. W., Lammers, T., & Wolfram, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115054 · Cited by 29
Nanozymes to fight the COVID-19 and future pandemics
Kumawat, M., Umapathi, A., Lichtfouse, É., & Daima, H. K. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01252-5 · Cited by 35
Bikdeli, B., Jiménez, D., Rodríguez, P. D., Valle, F. G., Porras, J. A., Barba, R., Ay, C., Malý, R., Braester, A., Imbalzano, E., et al. (2022) · Viruses · doi:10.3390/v14020178 · Cited by 27
da Silva, M. K., Campos, D. M. D. O., Akash, S., Akter, S., Leow, C. Y., Fulco, U. L., & Oliveira, J. I. N. (2023) · Viruses · doi:10.3390/v15102130 · Cited by 30
Einarsdottir, S., Martner, A., Waldenström, J., Nicklasson, M., Ringlander, J., Arabpour, M., Törnell, A., Wiktorin, H. G., Nilsson, S., Bittar, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006937 · Cited by 29
Beyond the Individual: Community‐Centric Approaches to Increase Diversity in Biomedical Research
Brown, K. E., Fohner, A. E., & Woodahl, E. L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2808 · Cited by 29
Self-splicing RNA circularization facilitated by intact group I and II introns
Shen, Y. H., Li, B., Dong, L., Tang, W., Ren, J., Chen, F., Zheng, W., Yu, Y. F., Gao, L., & Wei, W. (2025) · Nature Communications · doi:10.1038/s41467-025-62607-y · Cited by 31
Affeldt, P., Koehler, F. C., Brensing, K. A., Gies, M., Platen, E., Adam, V., Butt, L., Grundmann, F., Heger, E., Hinrichs, S., et al. (2022) · Viruses · doi:10.3390/v14122646 · Cited by 27
Gan, L., Chen, Y., Tan, J., Wang, X., & Zhang, D. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07735-2 · Cited by 29
Autoimmune Hemolytic Anemia After mRNA COVID Vaccine
Fatima, Z., Reece, B. A., Moore, J. S., et al. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211073258 · Cited by 26
Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2023) · Advanced Materials · doi:10.1002/adma.202306246 · Cited by 30
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome
Ryder, S. P., Morgan, B. R., Coskun, P., Antkowiak, K. R., & Massi, F. (2021) · Evolutionary Bioinformatics · doi:10.1177/11769343211014167 · Cited by 25
COVID-19 Vaccination and Estimated Public Health Impact in California
Tan, S. T., Park, H. J., Rodríguez-Barraquer, I., Rutherford, G. W., Bibbins-Domingo, K. B., Schechter, R., & Lo, N. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8526 · Cited by 28
Smith, M. R., Trofimova, M., Weber, A., Duport, Y., Kühnert, D., & von Kleist, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26267-y · Cited by 30
Murer, L., Volle, R., Andriasyan, V., Petkidis, A., Gómez-González, A., Yang, L., Meili, N., Suomalainen, M., Bauer, M., Sequeira, D. P., et al. (2022) · Current Research in Virological Science · doi:10.1016/j.crviro.2022.100019 · Cited by 25
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticles
Escalona-Rayo, O., Papadopoulou, P., Slütter, B., & Kros, A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103041 · Cited by 29
Aspirin in COVID-19: Pros and Cons
Zareef, R. O., Diab, M. M., Saleh, T. A., Makarem, A., Younis, N. K., Bitar, F. F., & Arabi, M. T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849628 · Cited by 27
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.